Copyright
©The Author(s) 2020.
World J Clin Cases. Nov 6, 2020; 8(21): 5104-5115
Published online Nov 6, 2020. doi: 10.12998/wjcc.v8.i21.5104
Published online Nov 6, 2020. doi: 10.12998/wjcc.v8.i21.5104
Variable | All patients (n = 248) | IVBC group (n = 99) | EVBC group (n = 96) | TVBC group (n = 53) | P value |
Age | |||||
< 70 yr | 128 (51.6) | 51 (51.5) | 56 (58.3) | 21 (39.6) | 0.09 |
≥ 70 yr | 120 (48.4) | 48 (48.5) | 40 (41.7) | 32 (60.4) | |
ASA | |||||
I | 23 (9.3) | 9 (9.1) | 10 (10.4) | 4 (7.5) | 0.07 |
II | 167 (67.3) | 68 (68.7) | 70 (72.9) | 29 (54.7) | |
III | 58 (23.4) | 22 (22.2) | 16 (16.7) | 20 (37.7) | |
Gender | |||||
Male | 122 (49.2) | 52 (52.5) | 46 (47.9) | 24 (45.3) | 0.66 |
Female | 126 (50.8) | 47 (47.5) | 50 (52.1) | 29 (54.7) | |
Smoke | |||||
No | 204 (82.3) | 79 (79.8) | 83 (86.5) | 42 (79.2) | 0.39 |
Yes | 44 (17.7) | 20 (20.2) | 13 (13.5) | 11 (20.8) | |
Gross hematuria | |||||
No | 79 (31.9) | 31 (31.3) | 28 (29.2) | 20 (37.7) | 0.56 |
Yes | 169 (68.1) | 68 (68.7) | 68 (70.8) | 33 (62.3) | |
Urinary cytology | |||||
Negative | 77 (31.0) | 28 (28.3) | 34 (35.4) | 15 (28.3) | 0.50 |
Positive | 171 (69.0) | 71(71.7) | 62 (64.6) | 38 (71.7) | |
Tumor side | |||||
Left | 134 (54.0) | 50 (50.5) | 52 (54.2) | 32 (60.4) | 0.51 |
Right | 114 (46.0) | 49 (49.5) | 44 (45.8) | 21 (39.6) | |
Tumor location | |||||
Renal pelvis | 111 (44.8) | 37 (37.4) | 42 (43.8) | 32 (60.4) | 0.03 |
Upper and middle ureter | 66 (26.6) | 25 (25.3) | 25 (26.0) | 16 (30.2) | |
Lower ureter | 49 (19.8) | 26 (26.3) | 20 (20.8) | 3 (5.7) | |
Multiple | 22 (8.9) | 11 (11.1) | 9 (9.4) | 2 (3.8) | |
pT stage | |||||
pT0-pTa-pT1-pTis | 69 (27.8) | 27 (27.3) | 23 (24.0) | 19 (35.8) | 0.17 |
pT2 | 69 (27.8) | 31 (31.3) | 22 (22.9) | 16 (30.2) | |
pT3 | 107 (43.1) | 39 (39.4) | 51 (53.1) | 17 (32.1) | |
pT4 | 3 (1.2) | 2 (2.0) | 0 (0.0) | 1 (1.9) | |
LN status | |||||
LN-negative | 238 (96.0) | 94 (94.9) | 93 (96.9) | 51(96.2) | 0.787 |
LN-positive | 10 (4.0) | 5 (5.1) | 3 (3.1) | 2 (3.8) | |
Tumor grade | |||||
Low | 29 (11.7) | 14 (14.1) | 9 (9.4) | 6 (11.3) | 0.58 |
High | 221 (88.3) | 85 (85.9) | 87 (90.6) | 47 (88.7) | |
LVI | |||||
Negative | 223 (89.9) | 92 (92.9) | 84 (87.5) | 47 (88.7) | 0.43 |
Positive | 25 (10.1) | 7 (7.1) | 12 (12.5) | 6 (11.3) | |
Intravesical chemotherapy | |||||
No | 171 (69.0) | 75 (75.8) | 66 (68.8) | 30 (56.6) | 0.05 |
Yes | 77 (31.0) | 24 (24.2) | 30 (31.2) | 2 3 (43.4) | |
Adjuvant therapy | |||||
No | 218 (87.9) | 90 (90.9) | 80 (83.3) | 48 (90.6) | 0.21 |
Yes | 30 (12.1) | 9 (9.1) | 16 (16.7) | 5 (9.4) |
Variable | IRFS | CSS | OS | |||||||||||||||
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||||||||||
HR | 95%CI | P value | HR | 95%CI | P value | HR | 95%CI | P value | HR | 95%CI | P value | HR | 95%CI | P value | HR | 95%CI | P value | |
Age < 70 yr vs age ≥ 70 yr | 0.799 | 0.412-1.550 | 0.507 | - | 0.968 | 0.398-2.353 | 0.943 | 1.340 | 0.656-2.737 | 0.421 | ||||||||
Male vs female | 0.535 | 0.273-1.047 | 0.068 | - | 0.820 | 0.339-1.986 | 0.661 | 0.644 | 0.315-1.319 | 0.229 | ||||||||
BCE methods | 0.987 | - | 0.826 | 0.503 | ||||||||||||||
IVBC | 1 | Reference | - | - | 1 | Reference | - | 1 | Reference | - | ||||||||
EVBC | 1.032 | 0.474-2.246 | 0.937 | 0.707 | 0.235-2.128 | 0.537 | 0.587 | 0.223-1.542 | 0.280 | |||||||||
TUBC | 0.954 | 0.392-2.323 | 0.917 | 0.879 | 0.276-2.797 | 0.828 | 0.695 | 0.256-1.884 | 0.474 | |||||||||
Tumor location | 0.042 | 0.042 | 0.564 | 0.161 | ||||||||||||||
Lower ureter | 1 | Reference | - | 1 | Reference | - | 1 | Reference | - | 1 | Reference | - | ||||||
Middle and upper ureter | 0.421 | 0.177-1.002 | 0.051 | 0.421 | 0.177-1.002 | 0.051 | 0.930 | 0.295-2.933 | 0.901 | 1.148 | 0.451-2.920 | 0.772 | ||||||
Renal pelvis or calyx | 0.339 | 0.153-0.750 | 0.008 | 0.339 | 0.153-0.750 | 0.008 | 0.505 | 0.160-1.598 | 0.245 | 0.466 | 0.176-1.230 | 0.123 | ||||||
Multiple | 0.315 | 0.007-1.416 | 0.132 | 0.315 | 0.007-1.416 | 0.132 | 0.459 | 0.053-3.973 | 0.479 | 0.500 | 0.102-2.462 | 0.394 | ||||||
pT ≤ 2 vs pT > 2 | 0.567 | 0.273-1.178 | 0.128 | 9.156 | 2.673-31.358 | 0.000 | 8.439 | 2.424-29.377 | 0.001 | 2.970 | 1.417-6.225 | 0.004 | 2.891 | 1.364-6.128 | 0.006 | |||
LN (-/x) vs LN (+) | 0.901 | 0.123-6.586 | 0.918 | 16.793 | 6.328-44.568 | 0.000 | 14.343 | 5.176-39.745 | < 0.001 | 9.917 | 3.995-24.621 | 0.000 | 9.473 | 3.75-23.926 | < 0.001 | |||
Tumor grade | 0.988 | 0.383-2.547 | 0.980 | 25.367 | 0.083-7755.852 | 0.268 | 0.981 | 0.341-2.826 | 0.972 | |||||||||
LV (-) vs LV (+) | 0.611 | 0.146-2.552 | 0.499 | 2.933 | 0.969-8.881 | 0.057 | 2.385 | 0.907-6.273 | 0.078 | |||||||||
Urinary cytology | 0.993 | 0.478-2.064 | 0.986 | 1.474 | 0.492-4.419 | 0.488 | 1.446 | 0.592-3.532 | 0.418 | |||||||||
Intravesical chemotherapy (yes vs no) | 1.023 | 0.503-2.081 | 0.950 | 0.606 | 0.202-1.816 | 0.371 | 0.852 | 0.380-1.909 | 0.697 |
- Citation: Lai SC, Wu PJ, Liu JY, Seery S, Liu SJ, Long XB, Liu M, Wang JY. Oncological impact of different distal ureter managements during radical nephroureterectomy for primary upper urinary tract urothelial carcinoma. World J Clin Cases 2020; 8(21): 5104-5115
- URL: https://www.wjgnet.com/2307-8960/full/v8/i21/5104.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i21.5104